Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
-1.72%
)
Bitcoin
70,471.99
(
-0.06%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: genisi post# 153238

Saturday, 12/01/2012 12:29:26 AM

Saturday, December 01, 2012 12:29:26 AM

Post# of 257268
RE: GILD PR



All patients receiving sofosbuvir/RBV became HCV RNA negative on treatment and relapse accounted for all virologic failures.





It's quite clear GILD found no resistant variants to sofosbuvir in this study. Did they also test for ribavirin resistance? The resistance profile of generic riba could be the achilles heel in successfully treating second-line GT3 failures.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today